Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company based in Australia, on Tuesday provided a regulatory update on paxalisib for the treatment of glioblastoma (GBM) following its Type C clinical meeting with the US Food and Drug Administration (FDA).
In July 2024, the company reported topline results from the GBM-AGILE study in which newly diagnosed unmethylated (NDU) patients with glioblastoma treated with paxalisib showed a clinically meaningful improvement in a prespecified secondary analysis for overall survival (OS) compared to standard of care. Based on these results and the data from all completed paxalisib clinical studies, Kazia requested a meeting with the FDA to discuss potential clinical and regulatory paths.
Following discussions with the FDA and feedback from Kazia's recent Type C meeting, the FDA's current position is that data on OS would generally not be appropriate for accelerated approval, but could be considered to support a traditional/standard approval. The Agency further stated that the secondary endpoint OS data from the GBM-AGILE study are supportive and informative for designing and executing a pivotal registrational study in pursuit of a standard approval.
Kazia noted that the company aligned with the FDA on key aspects of the design of a proposed registrational/pivotal phase 3 study, including patient population, primary endpoint, and the comparator arm to be used.
"We appreciate the extensive and thoughtful feedback from the FDA, which provides us with added clarity with respect to paxalisib's potential registration pathway for the treatment of patients with NDU glioblastoma," commented Dr. John Friend, Kazia's CEO. "We believe data from the GBM-AGILE trial, including the prespecified secondary endpoint, which demonstrated a 3.8-month OS improvement, provides evidence supporting a clinically meaningful efficacy signal that merits further testing paxalisib in this patient population in a larger, pivotal study."
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
Kelun-Biotech's SKB518 granted IND clearance by US FDA
Renalytix reports real-world impact of KidneyIntelX on targeted kidney disease treatment
Intas and Accord BioPharma complete acquisition of UDENYCA (pegfilgrastim-cbqv) business
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Halozyme Therapeutics' VYVGART Hytrulo prefilled syringe for self-injection receives US FDA approval